GlassScriptPhysician profile
Brian L Boes
NPI 1295784643
$7,559.06
in general payments reported to CMS, 2019-2025
43 companies · $205 in 2025
The $205 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $415 · 2020: $5,236 · 2021: $985 · 2022: $159 · 2023: $293 · 2024: $266 · 2025: $205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $417 · Food and Beverage: $347.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $416.87 |
| Food and Beverage | $346.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $5,004.23 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $471.48 | 2023-2025 | Austedo, Austedo Xr |
| Eisai INC. | $155.82 | 2019-2024 | |
| Neurelis, INC. | $149.11 | 2020-2021 | |
| Abbvie INC. | $146.35 | 2021-2025 | Ubrelvy |
| Ucb, INC. | $143.37 | 2019-2021 | |
| Biogen, INC. | $123.49 | 2019-2021 | |
| Lundbeck LLC | $115.90 | 2019-2023 | Vyepti |
| Lilly USA, LLC | $108.33 | 2019-2024 | Kisunla |
| Genzyme Corporation | $84.11 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $70.59 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $60.82 | 2019-2021 | |
| Genentech USA, INC. | $55.27 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $54.52 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $51.25 | 2020-2021 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Boes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.